Several clinic trials using other immune checkpoint inhibitors in lung cancer are ongoing, such as trials of therapies targeting lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-containing Protein 3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), human endogenous retrovirus‐H long terminal repeat‐associating protein 2 (HHLA2), and T cell Ig and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT). Here, LAG3 is linked to lung carcinoma.